A comparison of the growth promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients with ovarian tumours.
The growth promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients with ovarian malignancy, benign ovarian tumours and non-tumour related gynaecological conditions have been investigated using an ovarian carcinoma cell line (OAW 42), mesothelial cells (58MC) and rat kidney cells (NRK-49F). Colony stimulating activity (CSA) for tumour cells and transforming activity (TA) for mesothelial cells were weakly correlated, but whereas elevated TA was tumour-associated, CSA was not. However, TA was not cancer-associated and, although the difference between the mean TA values of benign and malignant cyst fluids was of borderline significance, some benign cyst fluids from cystadenomas showed high TA values. Higher levels of TA in the cystadenomas showed a significant correlation with the menopausal status of the patient and higher levels of TA in the malignant cyst fluid/peritoneal fluid groups were associated with more advanced disease. Results indicated that some fluids contained TGF-beta-like activity, but there was no direct evidence for the presence of TGF-alpha/EGF-like activity in the fluids. Heparin inhibited clonogenic growth of tumour cells but not mesothelial cells. The reduced CSA which was observed after treatment of fluids with both heparin and thrombin implicated coagulation factors in the manifestation of CSA. It was concluded that CSA in the fluids was due, at least partly, to fibrin coagulation, and TA was due to unknown growth factor(s) which may include TGF-beta-like activity. The results are discussed in the context of the aetiology of ovarian carcinoma, and the possible clinical significance of TA.
Wilson
A P
AP
Oncology Research Laboratory, Derby City Hospital, UK.
Fox
H
H
Scott
I V
IV
Lee
H
H
Dent
M
M
Golding
P R
PR
D000818:Animals; D001202:Ascitic Fluid / Q000503:physiopathology*; D001779:Blood Coagulation Factors / Q000494:pharmacology; D001826:Body Fluids / Q000502:physiology*; D002455:Cell Division / Q000187:drug effects; D002471:Cell Transformation, Neoplastic / Q000139:chemically induced; D003115:Colony-Stimulating Factors / Q000494:pharmacology / Q000502:physiology*; D003560:Cysts / Q000503:physiopathology*; D004815:Epidermal Growth Factor / Q000494:pharmacology; D005260:Female; D006133:Growth Substances / Q000494:pharmacology / Q000502:physiology*; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D051379:Mice; D010051:Ovarian Neoplasms / Q000473:pathology*; D013917:Thrombin / Q000494:pharmacology; D016212:Transforming Growth Factor beta / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D001779:Blood Coagulation Factors; D003115:Colony-Stimulating Factors; D006133:Growth Substances; D016212:Transforming Growth Factor beta; D004815:Epidermal Growth Factor; D006493:Heparin; D013917:Thrombin